(Journal Article): Glucagon-like peptide 1 (GLP-1) and eating.
 
Gutzwiller JP, Degen L, Heuss L, Beglinger C (Division of Gastroenterology, University Hospital, Basel, Switzerland.)
 
IN: Physiol Behav 2004; 82(1):17-19
Impact Factor(s) of Physiol Behav: 2.044 (2004), 2.027 (2003), 1.652 (2002), 1.328 (2001)

Fulltext:    HTML 

ABSTRACT: New information regarding gastrointestinal mechanisms that participate in the control of food intake has extended our understanding of appetite control. Although each new signaling pathway discovered in the gut is a potential target for drug development in the treatment of obesity, the growing number of such signaling molecules indicates that a highly complex process controls food intake. The present summary focuses on the role of glucagon-like peptide 1 (GLP-1) in this regulatory process. The different biological effects of GLP-1 (glucose-lowering properties, inhibition of appetite and food intake) provide a powerful impetus for development of GLP-1-based new drugs.

TYPE OF PUBLICATION: Review

Articles citing this article:

• Gallwitz B. New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins. Rev Diabetic Stud 2005. 2: 61-69.
  » Diabetes OD » Disease Management » T2DM » Metabolic Control » Anti-Hyperglycemic and Anti-Ap... » Incretin Hormones » GLP-1 » Effectivity of GLP-1 in Therap... » Journal Article